Cancer imaging: Novel concepts in clinical magnetic resonance imaging

Journal of Internal Medicine

Volumn 268, Issue 2, 2010, Pages 120-132

  Kwee, T C ^a   Takahara, T ^a   Klomp, D W J ^a   Luijten, P R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cancer; functional imaging; MRI; MRI guided therapy

Indexed keywords

FLUORODEOXYGLUCOSE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

CANCER DIAGNOSIS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HIGH INTENSITY FOCUSED ULTRASOUND; LYMPHOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

DIFFUSION MAGNETIC RESONANCE IMAGING; EMBOLIZATION, THERAPEUTIC; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; NEOPLASMS; ULTRASONIC THERAPY;

EID: 77954343920     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02243.x     Document Type: Review

References (75)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009 59 : 225 249.
2. Fineberg HV, Bauman R, Sosman M. Computerized cranial tomography. Effect on diagnostic and therapeutic plans. JAMA 1977 238 : 224 227.
3. Barentsz J, Takahashi S, Oyen W et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 2006 24 : 3234 3244.
4. Torigian DA, Huang SS, Houseni M, Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 2007 57 : 206 224.
5. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med 2008 49 : 17N 21N, 37N.
6. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007 242 : 360 385.
7. Von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006 238 : 405 422.
8. Hillner BE, Siegel BA, Liu D et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008 26 : 2155 2161.
9. Padhani AR. Dynamic contrast-enhanced MR imaging. Cancer Imaging 2000 1 : 52 63.
10. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006 24 : 3293 3298. (Pubitemid 46622069)
11. Stejskal E, Tanner J. Spin diffusion measurements: spin echoes in the presence of a time dependent field gradient. J Chem Phys 1965 42 : 288 292.
12. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology 2000 217 : 331 345.
13. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006 239 : 632 649.
14. Padhani AR, Liu G, Koh DM et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009 11 : 102 125.
15. Feuerlein S, Pauls S, Juchems MS et al. Pitfalls in abdominal diffusion-weighted imaging: how predictive is restricted water diffusion for malignancy. AJR Am J Roentgenol 2009 193 : 1070 1076.
16. Humphries PD, Sebire NJ, Siegel MJ, Olsen ØE. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 2007 245 : 848 854.
17. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002 32 : 47 59.
18. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004 22 : 275 282.
19. Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 2008 18 : 1937 1952.
20. Mori T, Nomori H, Ikeda K et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 2008 3 : 358 364. (Pubitemid 351489475)
21. Ohba Y, Nomori H, Mori T et al. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg 2009 138 : 439 445.
22. Nomori H, Mori T, Ikeda K et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 2008 135 : 816 822.
23. Ohno Y, Koyama H, Onishi Y et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008 248 : 643 654.
24. Takenaka D, Ohno Y, Matsumoto K et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009 30 : 298 308.
25. Ono K, Ochiai R, Yoshida T et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009 29 : 336 340.
26. Komori T, Narabayashi I, Matsumura K et al. 2 [Fluorine-18]-fluoro-2- deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007 21 : 209 215.
27. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006 24 : 3245 3251.
28. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007 25 : 4104 4109. (Pubitemid 47495868)
29. Hamstra DA, Galbán CJ, Meyer CR et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008 26 : 3387 3394.
30. Galbán CJ, Mukherji SK, Chenevert TL et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2009 2 : 184 190.
31. Ma B, Meyer CR, Pickles MD et al. Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging 2009 21 : 276 287.
32. Lee KC, Bradley DA, Hussain M et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007 9 : 1003 1011.
33. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005 46 : 983 995.
34. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med 2004 45 : 1509 1518.
35. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990 175 : 494 498. (Pubitemid 20135291)
36. Will O, Purkayastha S, Chan C et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 2006 7 : 52 60.
37. Thoeny HC, Triantafyllou M, Birkhaeuser FD et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009 55 : 761 769.
38. Kuhl CK, Träber F, Schild HH. Whole-body high-field-strength (3.0-T) MR Imaging in Clinical Practice. Part I. Technical considerations and clinical applications. Radiology 2008 246 : 675 696.
39. Kuhl CK, Träber F, Gieseke J et al. Whole-body high-field-strength (3.0-T) MR imaging in clinical practice. Part II. Technical considerations and clinical applications. Radiology 2008 247 : 16 35.
40. Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur Radiol 2005 15 : 946 959.
41. Krautmacher C, Willinek WA, Tschampa HJ et al. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T - initial experience. Radiology 2005 237 : 1014 1019.
42. Kuhl CK, Jost P, Morakkabati N, Zivanovic O, Schild HH, Gieseke J. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology 2006 239 : 666 676.
43. Heesakkers RA, Fütterer JJ, Hövels AM et al. Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience. Radiology 2006 239 : 481 487.
44. Von Falkenhausen MM, Lutterbey G, Morakkabati-Spitz N et al. High-field-strength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. Radiology 2006 241 : 156 166.
45. Hori M, Kim T, Murakami T et al. Uterine cervical carcinoma: preoperative staging with 3.0-T MR imaging - comparison with 1.5-T MR imaging. Radiology 2009 251 : 96 104.
46. Hori M, Kim T, Murakami T et al. MR imaging of endometrial carcinoma for preoperative staging at 3.0 T: comparison with imaging at 1.5 T. J Magn Reson Imaging 2009 30 : 621 630.
47. Aisen AM, Chenevert TL. MR spectroscopy: clinical perspective. Radiology 1989 173 : 593 599.
48. Ott D, Hennig J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993 186 : 745 752.
49. Swindle P, McCredie S, Russell P et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 2003 228 : 144 151.
50. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology 2004 232 : 599 605.
51. King AD, Yeung DK, Ahuja AT et al. Salivary gland tumors at in vivo proton MR spectroscopy. Radiology 2005 237 : 563 569.
52. Bartella L, Morris EA, Dershaw DD et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006 239 : 686 692.
53. Faria JF, Goldman SM, Szejnfeld J et al. Adrenal masses: characterization with in vivo proton MR spectroscopy - initial experience. Radiology 2007 245 : 788 797.
54. Klomp DW, Bitz AK, Heerschap A, Scheenen TW. Proton spectroscopic imaging of the human prostate at 7 T. NMR Biomed 2009 22 : 495 501.
55. Jolesz FA. MRI-guided focused ultrasound surgery. Annu Rev Med 2009 60 : 417 430.
56. Mougenot C, Quesson B, de Senneville BD et al. Three-dimensional spatial and temporal temperature control with MR thermometry-guided focused ultrasound (MRgHIFU). Magn Reson Med 2009 61 : 603 614.
57. Bao A, Goins B, Dodd GD 3rd. et al. Real-time iterative monitoring of radiofrequency ablation tumor therapy with 15O-water PET imaging. J Nucl Med 2008 49 : 1723 1729.
58. Ram Z, Cohen ZR, Harnof S et al. Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery 2006 59 : 949 955.
59. Furusawa H, Namba K, Thomsen S et al. Magnetic resonance-guided focused ultrasound surgery of breast cancer: reliability and effectiveness. J Am Coll Surg 2006 203 : 54 63.
60. Okada A, Murakami T, Mikami K et al. A case of hepatocellular carcinoma treated by MR-guided focused ultrasound ablation with respiratory gating. Magn Reson Med Sci 2006 5 : 167 171.
61. Liberman B, Gianfelice D, Inbar Y et al. Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann Surg Oncol 2009 16 : 140 146.
62. Paliwal S, Mitragotri S. Ultrasound-induced cavitation: applications in drug and gene delivery. Expert Opin Drug Deliv 2006 3 : 713 726.
63. Breedis C, Young C. The blood supply of neoplasms in the liver. J Pathol 1954 30 : 969 977.
64. Murthy R, Nunez R, Szklaruk J et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005 25 (Suppl. 1 S41 55.
65. Bult W, Vente MA, Zonnenberg BA, Van Het Schip AD, Nijsen JF. Microsphere radioembolization of liver malignancies: current developments. Q J Nucl Med Mol Imaging 2009 53 : 325 335.
66. Mumper RJ, Ryo UY, Jay M. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumors. J Nucl Med 1991 32 : 2139 2143.
67. Nijsen JF, Seppenwoolde JH, Havenith T, Bos C, Bakker CJ, van het Schip AD. Liver tumors: MR imaging of radioactive holmium microspheres - phantom and rabbit study. Radiology 2004 231 : 491 499.
68. Seevinck PR, Seppenwoolde JH, de Wit TC et al. Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents. Anticancer Agents Med Chem 2007 7 : 317 334.
69. Seppenwoolde JH, Bartels LW, van der Weide R, Nijsen JF, van het Schip AD, Bakker CJ. Fully MR-guided hepatic artery catheterization for selective drug delivery: a feasibility study in pigs. J Magn Reson Imaging 2006 23 : 123 129.
70. Seppenwoolde JH, Nijsen JF, Bartels LW, Zielhuis SW, van Het Schip AD, Bakker CJ. Internal radiation therapy of liver tumors: qualitative and quantitative magnetic resonance imaging of the biodistribution of holmium-loaded microspheres in animal models. Magn Reson Med 2005 53 : 76 84.
71. Seevinck PR, Seppenwoolde JH, Zwanenburg JJ, Nijsen JF, Bakker CJ. FID sampling superior to spin-echo sampling for T2*-based quantification of holmium-loaded microspheres: theory and experiment. Magn Reson Med 2008 60 : 1466 1476.
72. Radioactive holmium microspheres for the treatment of liver metastases (HEPAR). Available at: http://clinicaltrials.gov/ct2/show/NCT01031784?term= holmium&rank=1. Accessed on 24 February 2010.
73. Verellen D, Ridder MD, Linthout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007 7 : 949 960.
74. Lagendijk JJ, Raaymakers BW, Raaijmakers AJ et al. MRI/LINAC integration. Radiother Oncol 2008 86 : 25 9.
75. Raaymakers BW, Lagendijk JJ, Overweg J et al. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol 2009 54 : N229 37.